Cost Curve News - News - https://www.costcurvenews.com/blog/page/14/

Lilly Expands Its Pharm-to-Table Offering, Promotes a Lower Price for Consistent Use

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

Regulating DTC Is All the Rage, Suddenly. But It Turns Out that Americans Do Want to Hear from Brands

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

Vaccine Politics and Policy Have Gone Off the Rails. Let’s Hope Reimbursement Stays on Track

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

There Has Been a Small Deluge of MFN News Over the Past 24 Hours, But Does It Matter?

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

A Parade of Pharma Execs Have Been Asked About MFN This Week, and the Commentary Is (Unintentionally) Revealing

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

MFN ‘Conversations’ Have Started, Pfizer’s Bourla Says, But There’s Not Much There There

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

Lilly Says Lists Prices Rose 3.8% Last Year, Though the Net Prices Tell a More Fascinating Story

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

APEX Special Edition: All Things IRA

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

APEX Special Edition: All Things Price and Oncology

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Cost Curve News

Pfizer’s Pricing Transparency Disclosures Are Out; The Company’s Net Prices Fell 2% Last Year

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv

7 months ago

Keep Reading

Lilly Expands Its Pharm-to-Table Offering, Promotes a Lower Price for Consistent Use

Regulating DTC Is All the Rage, Suddenly. But It Turns Out that Americans Do Want to Hear from Brands

Vaccine Politics and Policy Have Gone Off the Rails. Let’s Hope Reimbursement Stays on Track

There Has Been a Small Deluge of MFN News Over the Past 24 Hours, But Does It Matter?

A Parade of Pharma Execs Have Been Asked About MFN This Week, and the Commentary Is (Unintentionally) Revealing

MFN ‘Conversations’ Have Started, Pfizer’s Bourla Says, But There’s Not Much There There

Lilly Says Lists Prices Rose 3.8% Last Year, Though the Net Prices Tell a More Fascinating Story

APEX Special Edition: All Things IRA

APEX Special Edition: All Things Price and Oncology

Pfizer’s Pricing Transparency Disclosures Are Out; The Company’s Net Prices Fell 2% Last Year

Latest Posts

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Popular

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

Latest News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Subcribe To Newsletter